Walleye Capital LLC Invests $2.13 Million in COMPASS Pathways plc (NASDAQ:CMPS)

Walleye Capital LLC bought a new stake in COMPASS Pathways plc (NASDAQ:CMPS - Free Report) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 337,456 shares of the company's stock, valued at approximately $2,126,000. Walleye Capital LLC owned approximately 0.49% of COMPASS Pathways at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in CMPS. Logos Global Management LP grew its position in shares of COMPASS Pathways by 349.3% in the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company's stock valued at $7,001,000 after purchasing an additional 901,050 shares during the last quarter. Renaissance Technologies LLC boosted its position in COMPASS Pathways by 1,518.4% during the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company's stock worth $1,593,000 after acquiring an additional 247,500 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in COMPASS Pathways during the second quarter worth approximately $664,000. Tidal Investments LLC boosted its holdings in shares of COMPASS Pathways by 43.6% in the 1st quarter. Tidal Investments LLC now owns 19,082 shares of the company's stock valued at $159,000 after purchasing an additional 5,795 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of COMPASS Pathways in the 1st quarter valued at $201,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

COMPASS Pathways Stock Performance

Shares of NASDAQ CMPS traded down $0.21 during midday trading on Wednesday, hitting $4.14. The company's stock had a trading volume of 617,217 shares, compared to its average volume of 630,154. COMPASS Pathways plc has a 1-year low of $4.05 and a 1-year high of $12.75. The firm's fifty day moving average price is $5.53 and its 200-day moving average price is $6.50. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The firm has a market cap of $283.26 million, a P/E ratio of -1.98 and a beta of 2.24.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.60) by $0.04. During the same quarter last year, the business earned ($0.67) EPS. On average, sell-side analysts forecast that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CMPS has been the topic of a number of research reports. HC Wainwright cut their target price on shares of COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Cantor Fitzgerald reissued an "overweight" rating on shares of COMPASS Pathways in a research note on Monday, September 9th. Maxim Group dropped their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Finally, Royal Bank of Canada dropped their price target on shares of COMPASS Pathways from $23.00 to $18.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $30.67.

Insider Buying and Selling at COMPASS Pathways

In other COMPASS Pathways news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the business's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $6.05, for a total transaction of $16,093,000.00. Following the sale, the insider now directly owns 6,905,774 shares in the company, valued at approximately $41,779,932.70. The trade was a 27.81 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.25% of the stock is currently owned by company insiders.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.